Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 41.5% in July

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw a significant decline in short interest in July. As of July 31st, there was short interest totaling 13,660,000 shares, adeclineof41.5% from the July 15th total of 23,360,000 shares. Based on an average daily trading volume, of 5,700,000 shares, the short-interest ratio is currently 2.4 days. Currently,6.1% of the shares of the stock are short sold. Currently,6.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 5,700,000 shares, the short-interest ratio is currently 2.4 days.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.58 on Monday. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $3.18. The company has a market cap of $174.99 million, a PE ratio of -2.00 and a beta of 1.18. The stock’s fifty day moving average price is $0.52 and its two-hundred day moving average price is $0.70.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. On average, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SGMO. Point72 Asset Management L.P. bought a new position in Sangamo Therapeutics in the 4th quarter valued at approximately $2,316,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $1,744,000. Wasatch Advisors LP boosted its holdings in shares of Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after acquiring an additional 1,215,653 shares in the last quarter. GSA Capital Partners LLP grew its position in Sangamo Therapeutics by 2,962.2% during the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after acquiring an additional 934,649 shares during the last quarter. Finally, Acuta Capital Partners LLC acquired a new position in Sangamo Therapeutics in the 4th quarter worth about $755,000. 56.93% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SGMO has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th. Wall Street Zen upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Barclays decreased their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.